Supplemental material
Leukemia & Lymphoma
Volume 63, 2022 - Issue 3
Original Articles
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia
Zoe K. McQuiltena Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia;b Department of Haematology, Monash Health, Melbourne, AustraliaCorrespondence[email protected]
https://orcid.org/0000-0001-9698-7185View further author information
https://orcid.org/0000-0001-9698-7185View further author information, , John F. Seymourc Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia;d Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australiahttps://orcid.org/0000-0003-2188-6835View further author information
https://orcid.org/0000-0003-2188-6835View further author information, , Erica M. Wooda Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia;b Department of Haematology, Monash Health, Melbourne, Australiahttps://orcid.org/0000-0001-7527-2340View further author information
https://orcid.org/0000-0001-7527-2340View further author information, , Robert Weinkovej Wellington Blood & Cancer Centre, Capital & Coast District Health Board, Wellington, New Zealand;k Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand;l Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealandhttps://orcid.org/0000-0003-3645-7988View further author information
https://orcid.org/0000-0003-3645-7988View further author information & on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG) show all